A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 434
- Population
- ALL · 50 Years
- Duration
- 2020-07-21 to 2023-05-18
- Intervention
- FYB203 (Proposed aflibercept biosimilar); Eylea® (Aflibercept)
- Comparator
- Eylea® (Aflibercept)
- Outcomes measured
- Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy…; Evaluate and Compare Functional Changes of the Retina by BCVA Over Time — Through study completion, until Week 56 (Visi…; Evaluate and Compare Changes in Foveal Center Point (FCP) Retinal Thickness — Through study completion, until Week 56 (…; Evaluate and Compare the Proportion of Patients Who Gain or Lose ≥ 5, 10, and 15 Early Treatment Diabetic Retinopathy S…; Evaluate and Compare the Absence of Disease Activity (Fluid-free Macula) Over Time — Through study completion, until We…; Evaluate and Compare Systemic Free Aflibercept Concentrations in a Subgroup of up to 60 Patients (up to 30 Per Arm) — A…; Evaluate and Compare Change in Vision-related Functioning and Well-being Measured by National Eye Institute Visual Func…; Evaluate and Compare the Immunogenic Profile (Anti-drug Antibodies [ADAs]) in Serum — Through study completion, until W…; Frequency of Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs) — Through study completion, unti…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.